Bristol Advisors’s AbbVie ABBV Stock Holding History

Bristol Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-4,900	Closed	-$452K	–	30
2018 Q4	$452K	Buy	4,900 +1,000	+26%	+$87.9K	0.54%	31
2018 Q3	$369K	Buy	+3,900	New	+$370K	0.61%	25
2018 Q1	–	Sell	-16,000	Closed	-$1.55M	–	33
2017 Q4	$1.55M	Buy	16,000 +12,989	+431%	+$1.22M	0.97%	27
2017 Q3	$316K	Buy	+3,011	New	+$229K	0.32%	49

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bristol Advisors's ABBV Position: Q1 2019 in Review

Bristol Advisors sold out of AbbVie (ABBV) in Q1 2019, closing a stake of 4,900 shares — an estimated $452K sold.

Bristol Advisors first reported a position in ABBV in Q3 2017 and held it in 4 quarters. The position peaked at $1.55M in Q4 2017. 2,034 funds tracked by Wall St. Rank hold ABBV as of Q1 2019.

Bristol Advisors reported no remaining AbbVie position as of Q1 2019 after selling out during the quarter.
Bristol Advisors sold 4,900 AbbVie shares in Q1 2019, an estimated $452K.
Bristol Advisors first reported a position in AbbVie in Q3 2017 and held it in 4 quarters.
Bristol Advisors's AbbVie position peaked at $1.55M in Q4 2017.
2,034 funds tracked by Wall St. Rank held AbbVie as of Q1 2019.

Based on Bristol Advisors's 13F filing for Q1 2019, filed 29 Apr 2019.